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Abstract
Synucleins (Syn), a family of synaptic proteins, includes -Syn, which plays a pivotal role in Parkinson’s disease and related
neurodegenerative diseases (synucleinopathies) by forming distinct brain pathologies (Lewy bodies and neurites). Since traumatic brain
injury (TBI) is a poorly understood risk factor for Parkinson’s disease, we examined the effects of TBI in the young and aged mouse brain
on -, -, and -Syn. Immunohistochemical analysis showed that brains from sham-injured young and aged mice had normal - and -Syn
immunoreactivity (IR) in neuropil of cortex, striatum, and hippocampus with little or no -Syn IR. At 1 week post TBI, the aged mouse
brain showed a transient increase of - and -Syn IR in the neuropil as well as an induction of -Syn IR in subcortical axons. This was
associated with strong labeling of striatal axon bundles by antibodies to altered or nitrated epitopes in -Syn as well as by antibodies to
inducible nitric oxide synthase. However, these TBI-induced changes disappeared by 16 weeks post TBI, and altered Syn IR was not seen
in young mice subjected to TBI nor in -Syn knockout mice while Western blots confirmed that TBI induced transient alterations of -Syn
in the mouse brains. This model of age-dependent TBI-induced transient alterations in -Syn provides an opportunity to examine possible
links between TBI and mechanisms of disease in synucleinopathies.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Synuclein (Syn) proteins are directly implicated in hu-
man diseases since -Syn gene mutations have been iden-
tified in rare kindreds with familial Parkinson’s disease
(PD) (Polymeropoulos et al., 1997; Kruger et al., 1998), and
-Syn inclusions occur in hereditary and sporadic PD
(Arima et al., 1998; Tu et al., 1998; Arawaka et al., 1998;
Spillantini et al., 1997, 1998; Irizarry et al., 1998; Baba et
al., 1998; Duda et al., 2002). Previous studies have shown
that -Syn is the primary building block of filamentous
Lewy bodies (LBs) and dystrophic Lewy neurites in PD and
related disorders known as synucleinopathies (Baba et al.,
1998; Giasson et al., 2000b). In addition, -Syn forms
filaments in vitro and -Syn transgenic animals develop
LB-like inclusions associated with neurodegeneration (Au-
luck et al., 2002; Conway et al., 1998; Feany and Bender
2000; Masliah et al., 2000; Giasson et al., 2000a; Paxinou et
al., 2001). Moreover, -Syn in human synucleinopathy
brains is pathologically altered by ubiquitination, phosphor-
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ylation, nitration, and conformational modifications (Duda
et al., 2002; Giasson et al., 2000a; Fujiwara et al., 2002).
Mechanistic insights into disease processes underlying
PD and related disorders have evolved substantially since
the link between these diseases and -Syn pathology was
discovered, but it is not yet known how normal -Syn is
transformed from a highly soluble synaptic protein into
filamentous perikaryal aggregates in the disease state (Tro-
janowski and Lee., 2002). Although the genetic determi-
nants of late-onset PD are uncertain (Tanner et al., 1999),
traumatic brain injury (TBI) has been identified as an envi-
ronmental risk factor for sporadic PD (Nayernouri, 1985;
Factor and Weiner, 1991; Stern, 1991), in addition to ex-
posure to neurotoxins (Langston et al., 1983; Hubble et al.,
1993; Przedborski and Jackson-Lewis, 1998; Betarbet et al.,
2000). Although the brains of patients with dementia pugi-
listica are characterized by plaques and tangles similar to
those seen in Alzheimer’s disease (AD), the abnormal ac-
cumulation of -Syn in axonal swellings and dystrophic
neurites in these brains suggests a possible link between
TBI and the development of -Syn pathology in PD (New-
ell et al., 1999), which could be mediated by TBI-induced
oxidative and nitrative stress (Mesenge et al., 1988). Indeed,
experimental TBI has been shown to cause oxidative stress
in wild-type (WT) mice (Pratico et al., 2002) and in Tg
mouse models (Tg2576) of AD-like amylodosis (Uryu et
al., 2002). Further, TBI-induced oxidative stress was asso-
ciated with an augmentation of A levels and deposits in the
brains of Tg2576 mice (Uryu et al., 1993). Thus, emerging
data indicate that TBI causes chronic as well as acute
neurodegeneration (Maxwell et al., 1997; McIntosh et al.,
1998; Uryu et al., 2002). Nonetheless, experimental evi-
dence directly linking TBI to the development of -Syn
pathology or any other abnormalities in PD and related
disorders has not been obtained.
Thus, we addressed this issue by examining the effects of
TBI on the expression of -, -, and -Syn in WT mice
subjected to controlled cortical impact (CCI) injury, and our
studies revealed that TBI induces transient nitrative alter-
ations in -Syn similar to those seen in PD and related
synucleinopathies.
Materials and methods
Antibodies
The panel of antibodies to -, -, and -Syn as well as to
other proteins studied here in summarized in Table 1 to-
gether with the provenance and citations on the character-
ization and properties of these antibodies.
Animals and injury
The CCI paradigm for TBI was applied to 4-month-old
(young) (n  35) and 24-month-old (aged) WT mice (n 
25) with (B6D2F1 background) and to 16-month-old -Syn
knockout (KO) mice (n  6; kindly provided by Dr. Asa
Abeliovich) (Abeliovich et al., 2000). The procedures for
CCI have been described in detail elsewhere (Murai et al.,
1998; Nakagawa et al., 1999, 2000). Briefly, an anesthetized
mouse was mounted on the stereotactic frame, the scalp and
temporal muscle were reflected, and 5-mm craniectomy was
performed (centered between the lambda and bregma over
the left parietal cortex) with the dura remaining intact. CCI
brain injury was produced as modified from the original
paradigm described by Dixon et al. (1991) by using a 3-mm
metal impounder driven at a velocity of 5.0 m/s to a depth
of 1.0 mm over a time frame of 100 ms as described (Murai
et al., 1998; Nakagawa et al., 1999, 2000). A transducer
attached to the device provided an analog signal recorded by
a computer program (R.C. Electronics, Santa Barbara, CA)
Table 1
List of antibodies
Antibodies Epitope/antigen Dilution Species Reference
Syn202 - and -Syn 1:20K Mouse Giasson et al., 2000b
SNL-1 -Syn (104–119) 1:5K Rabbit Giasson et al., 2000b
Syn207 -Syn 1:20K Rabbit Giasson et al., 2000b
-2 -Syn 1:2K Rabbit This study
Syn102 -, -Syn, C-terminus (130–140) 1:1K Mouse Giasson et al., 2000b
Syn119 -Syn, NAC 1:1K Mouse This study
Syn205 -, -Syn, C-terminus (130–140) 1:1K Mouse Giasson et al., 2000b
Syn214 -, -Syn, C-terminus (130–140) 1:1K Mouse Giasson et al., 2000b
Syn303 Conformational -  -  -Syn (-Syn N-terminus) 1:500 Mouse Duda et al., 2002
Syn505 Conformational -  -  -Syn (-Syn N-terminus) 1:500 Mouse Duda et al., 2002
Syn506 Conformational -  -  -Syn (-Syn N-terminus) 1:500 Mouse Duda et al., 2002
Syn514 Conformational -  -  -Syn (-Syn N-terminus) 1:500 Mouse Duda et al., 2002
-1 -Syn 1:1K Mouse Giasson et al., 2001
nSyn14 Nitrated -Syn Neat Mouse Giasson et al., 2000a
iNOS-2 INOS 1:50 Rabbit Santa Cruz Biotech
LN-39 APP 1:50 Mouse Nakagawa et al., 2000
NFL NFL 1:2k Rabbit Ishihara et al., 1999
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for monitoring impact parameters. Uninjured control mice
were surgically prepared in a similar manner, but they were
not subjected to CCI injury. After CCI brain injury, the
craniotomy was covered with a cranioplasty and the scalp
was sutured. All mice were allowed to recover on a heating
pad maintained at 37°C.
Sham and CCI mice were allowed to survive for various
time periods, as follows: young mice for 1, 3, 5 days, and 1,
9, and 16 weeks post injury, aged mice for 1, 9, and 16
weeks post injury, and aged -Syn KO mice for 1 week. All
of these procedures were performed in strict accordance
with the National Institutes of Health Guide for the Care
and Use of Laboratory Animals (National Research Coun-
cil, 1996) and they were approved by the Institutional An-
imal Care and Use Committee of the University of Penn-
sylvania.
Immunohistochemistry
For immunohistochemical analyses, animals were deeply
anesthetized and were perfused with saline followed by
10% neutral buffered formalin (NBF). The brain was re-
moved and fixed overnight with fresh 10% NBF, embedded
in paraffin, and a series of 6-m sections were cut for
immunohistochemistry (IHC) with and without the use of
antigen retrieval procedures as described (Uryu et al., 2002;
Murai et al., 1998; Nakagawa et al., 1999, 2000). Sections
from some mouse brains were pretreated prior to IHC with
anti-mouse IgG Fab (30 l/ml) (Jackson ImmunoResearch
Lab, Inc.) in donor horse serum (DHS) for 30 min to
eliminate background due to residual endogenous mouse
IgG. Sections were incubated with primary antibodies (see
Table 1) overnight and with an appropriate biotinylated
secondary antibody for 1 h. The avidin-biotin complex
method was used according to instructions of the vendor
(Vector Lab, Inc.) with 3,3-diaminobenzidine as chromo-
gen. The sections were counterstained with hematoxylin,
dehydrated in series of ethanol, cleared in xylene, and cov-
erslipped with paramount.
Colocalization of -Syn with neurofilament (NF) sub-
units, or with A precursor proteins (APP), was examined
by applying double fluorescence IHC (FIHC). For Syn303
to -Syn and the rabbit antiserum NFL to the low Mr NF
subunit (NFL), double FIHC was performed by incubating
sections with a mixture of the mouse monoclonal antibody
(mAb) Syn303 and polyclonal NFL antiserum overnight
and subsequently done with a mixture of Alexa 488-anti-
mouse IgG and Alexa 594-anti-rabbit IgG (Molecular
Probes, Inc.) for 2 h. For double FIHC using mAb Syn303
and mouse mAb LN-39 to APP, single FIHC was conducted
with Syn303, which was visualized with Alexa 488-anti-
mouse IgG followed by blocking sections with anti-mouse
IgG Fab in DHS (30 min). Subsequently, another round of
single FIHC was carried out by using the LN-39 mAb,
which was visualized by Alexa 594-anti-mouse IgG. Then,
the sections were treated with 3% of Sudan Black for 10
min (Romijn et al., 1999) to suppress autofluorescence and
mounted with Vectashield mounting medium with 4,6-dia-
midino-2-phenylindole (Vector Laboratories).
For all of IHC experiments, negative controls included
the application of the same IHC protocols to sections using
preimmune serum or DHS instead of primary antibody.
Analysis of stained sections was done by bright-field and
fluorescence microscopy by using an Olympus BX51 at-
tached to a CCD camera (ProgResC14, Jenoptic Camera
Europe Inc., Jena, Germany).
Western blot studies
For sequential biochemical fractionation and Western
blot studies of -Syn, selected unfixed brains were removed
and frozen with dry ice powder. Cortical and subcortical
regions subjacent to the impact site were excised from the
left hemisphere of the CCI mice and equivalent areas from
the right hemisphere also were excised for parallel studies
as controls. Each sample was weighed and homogenized in
3 ml/g of high salt (HS) buffer (50 mM Tris, pH 7.5, 750
mM NaCl, 5 mM EDTA) and a cocktail of protease inhib-
itors (1 mM phenylmethylsulfonyl and 1 mg/ml each of
pepstatin, leupeptin, N-tosyl-L-phenylalanyl chloromethyl
ketone, N-tosyl-lysine chloromethyl ketone, and soybean
trypsin inhibitor). The samples were sedimented at 100,000
 g for 20 min each. Pellets were reextracted with HS
buffer followed by two sequential extractions with 3 ml/g of
HS buffer containing 1% Triton X-100 (HS/T fraction). The
pellets were homogenized in 500 ml of HS buffer/1 M
sucrose and after centrifugation the floating myelin was
discarded. The pellets were extracted with 2 ml/g of RIPA
[50 mM Tris, pH 8.0, 150 mM NaCl, 5 mM EDTA, 1%
NP40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl
sulfate (SDS)] and sedimented at 100,000  g for 20 min.
Half of each pelleted sample was extracted with 1 ml/g
SDS-sample buffer (SDS fraction) by sonication and heat-
ing to 100°C for 10 min in or 70% formic acids (FA
fraction) by sonication. FA was removed by lyophilization
and the dried material was resuspended in 1 ml/g of SDS-
sample buffer by heating to 100°C for 10 min. Five micro-
liters of each fraction was loaded on separate lanes of 13%
polyacrylamide gels. Proteins were resolved on slab gels by
SDS–polyacrylamide gel electrophoresis (SDS-PAGE) and
electrophoretically transferred onto nitrocellulose mem-
branes (Schleicher and Schuell, Keene, NH) in buffer con-
taining 48 mM Tris, 39 mM glycine, and 10% methanol.
Membranes were blocked with a 5% solution of powdered
milk dissolved in Tris-buffered saline-Tween (50 mM Tris,
pH 7.6, 150 mM NaCl, 0.1% Tween 20), incubated with
primary antibodies followed with either a goat anti-mouse
or rabbit IgG horseradish peroxidase (HRP)-conjugated an-
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tibody (Jackson ImmunoResearch Lab), and visualized on
films using enhanced chemiluminescence reagents (NEN,
Boston, MA) or directly on the membrane with 3,3-diami-
nobenzidine as the chromogen.
Results
Recognition of CCI-injured areas
APP immunoreactivity (IR) was used to detect axons
damaged by CCI in brain subjacent to the impact site as
described (Pierce et al., 1998). In the aged mouse at 1 week
post TBI, APP IR was noted exclusively in areas ipsilateral
to the site of CCI, including the somatosensory and cingu-
late cortex, the corpus callosum, dorsolateral thalamus stri-
atum, globus pallidus and hippocampus, especially axons in
CA3 and fimbria, but the most severely affected structures
were striatal and pallidal axon bundles (Fig. 1A).
Transient effects of TBI on Syn IR in aged mouse brain
Staining patterns of -, -, and -Syn in normal mouse
have been previously described (Giasson et al., 2001), and
the brains of sham (uninjured) aged mice showed Syn IR
consistent with this previous report, whereas the brains of
mice subjected to CCI-induced TBI showed alterations in
the distribution of -, -, and -Syn confined to those areas
wherein APP IR was noted in damaged axons although
these alterations were not as dramatic as those revealed by
antibodies to APP (Fig. 1A).
In the sham-treated mouse brains, antibodies to -Syn
demonstrated light staining in the striatum (Fig. 1B) as well
as in cortex, thalamus, and hippocampus (not shown). How-
ever, TBI induced by CCI caused a modest enhancement of
-Syn (SNL-1) IR between 1 and 9 weeks post injury (Fig.
1A and B), especially in the neuropil of cortex, striatum, and
hippocampus (e.g., fimbria and CA3 region), but this was
only evident on high magnification (Fig. 1A and B). The
intensity of -Syn IR was reduced by 16 weeks post injury
to levels close to those seen in the sham-treated mice
wherein no diffuse axonal injury profiles or spheroids were
seen to exhibit APP IR or -Syn IR (Fig. 1B).
As in normal mice, -Syn (Syn207, -2) exhibited mod-
est IR in the neuropil of sham-treated mice in the same brain
areas wherein -Syn IR was located. However, the intensity
of -Syn IR was enhanced in the cortical neuropil near the
area of impact, as well as in the subjacent striatum (Fig. 1A
and B), the hilus of the hippocampus, and the dorsolateral
thalamus (not shown) 1 week following TBI in aged mice,
and this change also was evident only on high magnification
(Fig. 1A and B). The enhanced intensity of -Syn IR de-
creased at 9 weeks post injury, and by 16 weeks post injury,
it was identical to the normal staining pattern (Fig. 1B); but
infrequent -Syn IR axonal spheroids were seen in axons of
the corpus callosum and internal capsule (Fig. 1B, inset).
Scant -Syn (-1) IR was seen in the brains of sham
mice, but it was induced by CCI in the corticofugal axons of
the striatum at 1–9 weeks post injury (Fig. 1A and B). It
then diminished to normal levels by 16 weeks post injury.
Infrequent -Syn IR spheroids were seen in axons of the
internal capsule and corpus callosum at 9 and 16 weeks post
injury (Fig. 1B, inset).
Conformational/nitrative -Syn alterations in aged mouse
brains induced by TBI
Antibodies that recognize conformational (Syn303,
Syn505, Syn506, and Syn514) and or nitrative (nSyn14)
alterations of -Syn showed no IR in the sham-treated
mouse brain; but in the CCI-treated mice, these same anti-
bodies produced increased IR at 1 week post injury re-
stricted exclusively to the cortex near the injury site as well
as axon bundles of the striatum, corpus callosum, globus
pallidus, and the fimbria of brain ipsilateral to the site of
CCI (Fig. 2A–C and Fig. 3). Double FIHC with Syn303 and
NFL antibodies (Fig. 2C) showed that Syn303 IR colocal-
ized with a subset of NFL-positive fibrous elements, while
double FIHC using Syn303 and LN-39 antibodies revealed
-Syn IR colocalized with APP IR in damaged axons (Fig.
2D). The induction of conformational/nitrative alterations in
-Syn IR was noted only at 1 week post injury since this IR
was markedly reduced or undetectable by 9 weeks post
injury and beyond (Fig. 2A and B). Moreover, these tran-
sient alterations were most prominent in 24-month-old com-
pared to 4-month-old CCI-treated mice (Fig. 3). IHC re-
vealed that inducible nitric oxide synthase (iNOS) IR
appeared in those areas of the old but not young CCI-treated
mouse brains that contained conformational/nitratively al-
tered -Syn IR at 1 week post injury (Fig. 3), which sug-
gests that iNOS induction may be linked to the abnormal
transient nitration of -Syn in damaged axons.
Despite that this -Syn axonal pathology was most
prominent in the 24-month-old CCI-treated mice, the brains
of CCI-treated 4-month-old mice killed at 1 and 5 days post
TBI showed IR for nitrated -Syn in cortical neurons near
the impact site (Fig. 4A), but antibodies to conformationally
altered epitopes in -Syn did not produce convincing IR
(Fig. 4B). Similar staining patterns also were noted in aged
mice (data not shown).
Finally, IHC with all of the antibodies against -Syn
used in the present study, including antibodies against con-
formationally and nitratively altered forms of -Syn, failed
to demonstrate any IR in aged -Syn KO mice at 1 week
post injury (Fig. 5A).
Western blot analyses of aged mouse brain following TBI
Brains from control or sham-treated WT mice and aged
WT mice subjected to TBI that were examined 1 week post
CCI showed comparable levels of monomeric -Syn in
Western blots of the high-salt and Triton X-100 fractions
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(but not the SDS fraction) probed with Syn303 (Fig. 5B). In
addition, Syn303 also recognized murine -Syn, and it was
evident that the brains from both the sham- and CCI-treated
mice also contained similar levels of -Syn. However, using
the same mAb and Western blot conditions, the brains from
sham- and CCI-treated -Syn KO mouse 1 week post injury
Fig. 1. In the aged wild-type mouse brain, A precursor proteins (APP) immunoreactivity (IR) delineates the damaged area induced by controlled cortical
impact (CCI) wherein altered synuclein (Syn) IR also occurs. (A) Low-power views of APP, -, -, and -Syn IR at 1 week post traumatic brain injury (TBI).
APP IR identifies the area of CCI-induced damage and antibodies to - (SNL-1), - (Syn207), and -Syn (-1) also show variable changes in IR in the same
region, but these are more evident when viewed at higher magnification as shown in B using a composite set of images. (B) High-power views of -, -,
and -Syn IR to at 1, 9, and 16 weeks post TBI in the striatum. At 1 and 9 weeks post TBI, there is an increase axonal IR for -Syn, while only - and -Syn
show increased neuropil IR. In addition, antibodies to - and -Syn demonstrate scattered axonal white matter spheroids (inset). In contrast, at 16 weeks post
TBI, the changes in Syn IR noted above have decreased to control levels.
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showed no evidence of authentic monomeric -Syn, al-
though monomeric -Syn was detected in the high-salt and
Triton X-100 fractions but not in the SDS fraction (Fig. 5B).
Interestingly, 45- and 50-kDa Mr immunobands were noted
in the SDS fraction of the brain from the TBI-treated WT
mouse brain (Fig. 5B), but they were not seen in the SDS or
Fig. 2. In the aged mouse brain, -Syn undergoes conformational and nitrative modifications associated with inducible nitric oxide synthase (iNOS) induction
following traumatic brain injury (TBI). (A) High-power views of conformationally altered -Syn (Syn303) immunoreactivity (IR) seen mainly at 1 week post
TBI in the cortex, striatum, and hippocampus, but not in these same regions at 9 and 16 weeks post TBI or in sham-treated wild-type mice. (B) High-power
views of nitrated -Syn (nSyn14) IR at 1 week post TBI in the striatum, but not at 9 and 16 weeks post TBI. (C and D) High-power images of double
fluorescence immunohistochemistry (FIHC) with anti-conformational -Syn (Syn303) and anti-NFL antibodies (C) or -Syn (Syn303) and APP (LN-39)
antibodies at 1 week post TBI in the striatum (D). This double FIHC (see merged images) reveals that the abnormal -Syn accumulates in axons in the
controlled cortical impact-damaged area of the brain. NFL, low Mr NF subunit; APP, A precursor protein.
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Fig. 3. Comparison of immunoreactivity (IR) for normal -Syn, conformationally altered -Syn, nitrated -Syn, and inducible nitric oxide synthase (iNOS)
IR between young and aged wild-type mouse brains at 1 week post traumatic brain injury (TBI). The young (4 month old) mouse brain (A) shows little IR
for conformationally altered (Syn303) or nitrated -Syn (nSyn14) nor for iNOS (iNOS-2) at 1 week post TBI, compared to the localized enhanced IR for
these proteins in the aged mouse brain (B) in the brain region subjacent to the impact site for controlled cortical impact.
Fig. 4. Limited nitration of -Syn detected in the brains of young wild-type mice following controlled cortical impact (CCI). (A) The young mouse brain
shows nitrated -Syn (nSyn14) immunoreactivity (IR) in cortical neurons subjacent to the site of CCI from 1 through 5 days post traumatic brain injury (TBI),
whereas this IR diminishes and is no longer detectable at 1 week post TBI. (B) Conformationally altered -Syn (Syn303) IR is not seen in young mice at
any time including the times shown in B.
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any of the other fractions of the brains from the sham-
treated WT mouse or the -Syn KO mice. Since either or
both of these bands could represent the transiently modified
species of -Syn induced by CCI that were detected by IHC,
as described above, we examined these immunobands fur-
ther.
Briefly, the SDS fractions of brain from the TBI-treated
aged WT mice at 1 week post CCI were subjected to
Western blot analysis with multiple additional antibodies to
different -Syn epitopes including those in the C-terminal
(SNL-1, Syn102, Syn205, Syn214), central (“NAC”).
(Syn119, Syn129), and N-terminal (Syn303, Syn505,
Syn506, Syn514) domains of -Syn as well as to nitrated
epitopes (including Tyr39) in -Syn (nSyn14) and with an
antibody to -Syn (Syn 207). Notably, all of the antibodies
specific for epitopes in -Syn consistently recognized a
45-kDa immunoband (Fig. 5C) that was not detected by the
anti--Syn antibody and therefore probably corresponds to
the transiently modified species of -Syn induced by TBI in
the aged WT mice. Although some of these anti--Syn
antibodies inconsistently detected other higher and lower
Mr protein bands (data not shown), they do not appear to be
reproducible products of TBI-induced modifications in
-Syn because they were not recognized consistently by the
entire panel of anti--Syn antibodies as was the case for the
45-kDa band described above.
Fig. 5. (A). The aged -Syn knockout (KO) mouse brain shows no -Syn immunoreactivity (IR) following traumatic brain injury (TBI). Immunohisto-
chemistry using antibodies to conformationally altered (Syn303) and nitrated (nSyn14) -Syn shows no IR in the aged -Syn KO mouse at 1 week post TBI,
thereby confirming the specificity of the -Syn IR seen in the aged wild-type (WT) mouse brain following TBI. (B and C) Western blot analysis shows a
45-kDa Mr protein in the insoluble fraction in the aged mouse brain following TBI that is recognized by multiple anti--Syn antibodies. (B) As molecular
standards, 20 ng of recombinant human -Syn (lane 1), -Syn (lane 2), or - and -Syn (lane 3) were loaded in the far left panel. The high-salt and Triton-X
fractions of aged control (Ctr) WT (Aged) and -Syn KO (KO) mice subjected to controlled cortical impact (CCI) (TBI) show equivalent levels of monomeric
-Syn, but only the WT mice show monomeric -Syn immunobands that migrate just below the -Syn immunobands. This is seen more clearly in the less
exposed portion of the same Western blot that is shown in the separate box below the illustration of the entire Western blot identified with an arrow and
asterisk as well as arrows pointing to the -Syn and -Syn immunobands. Note that only the brain of the CCI-treated WT mouse shows a 45-kDa immunoband
in the sodium dodecyl sulfate (SDS) fraction that is recognized by Syn303 (arrow in B). Samples were also analyzed by Western blotting for the presence
of -tubulin (bottom panels) as a control for the processing and gel loading of samples. (C) Numerous other anti--Syn antibodies, including those that
recognize epitopes extending from the N-terminus to the C-terminus of -Syn and nitrated -Syn also consistently detect the same 45-kDa immunoband in
the SDS fraction from the brain of the CCI-treated WT mouse, but this band is not detected by an anti--Syn (207) antibody.
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Discussion
Here we show that TBI induced by the CCI paradigm
transiently altered the distribution of -Syn, and post-trans-
lationally modified this synaptic protein in a unique manner,
but only in the aged (24 month old) WT mouse brain and
not in young (4 month old) WT mice. Significantly, these
changes in -Syn IR in the brains of old WT mice subjected
to CCI recapitulate some of the key features of -Syn
pathologies that are seen in the brains of patients with
synucleiopathies such as accumulations of -Syn in axons,
and the generation of nitratively as well as conformationally
modified forms of -Syn. Further, similar to authentic hu-
man synucleinopathies, these transient modifications and
alterations of -Syn were specific largely for this member of
the synuclein family of synaptic proteins since more modest
transient increases in IR for - and -Syn were detected by
IHC in brain sections with antibodies to each of these other
members of this family of proteins.
Since Braak and coworkers recently demonstrated that
the presence of axonal -Syn pathology in the brainstem of
patients with PD is one of the initial morphological mani-
festations of disease (Braak et al., 1999, 2003) and Duda
and his colleagues reported an unprecedented as well as
extensive burden of -Syn pathology in the striatum of the
brains of patients with different LB disorders (i.e., PD,
dementia with LBs or DLB, and AD plus DLB) (Duda et al.,
2002), it is plausible to consider that the axonal deposits of
-Syn as filamentous inclusions or nonfilamentous aggre-
gates are more significant mediators of neurological and
behavioral impairments than LBs themselves in synucle-
inopathies, especially since the abundance of LBs does not
always correlate robustly with such impairments (Hurtig et
al., 2000). Thus, our studies here showing an intra-axonal
localization of pathological -Syn in the striatum of aged
mouse brains following TBI using double FIHC with a
combination of antibodies to -Syn and either NFL or APP
may facilitate efforts to dissect out the biological signifi-
cance and underlying mechanisms of axonal -Syn pathol-
ogies.
Comparison of the IHC and Western blot data here
suggests that TBI induced a nitrative and conformational
modification of -Syn, especially in striatal axons, and the
45-kDa immunoband illustrated in Fig. 5C is likely to cor-
respond to this transiently altered form of -Syn micro-
scopic pathology since it was recognized by multiple dif-
ferent antibodies to diverse -Syn epitopes throughout the
N-terminal to C-terminal extent of -Syn as well as by
antibodies that recognize nitrated and conformationally
modified forms of this synaptic protein. In contrast, this
45-kDa protein was not recognized by antibodies specific
for -Syn. Although the relationship of this 45-kDa protein
to different species -Syn is not entirely clear, a recent
report described the induction of a similar 45-kDa -Syn--
like protein in PC12 cells treated with nerve growth factor
(NGF) for 1 week (Stefanis et al., 2001), and since TBI
induces neurotrophin upregulation (DeKosky et al., 1994),
it is possible that generation of this 45-kDa protein from
monomeric -Syn is a consequence of TBI mediated by
neurotrophins. Alternatively, this TBI-induced -Syn-like
protein may reflect the formation of a protein complex that
results from the interaction of -Syn with itself or with
other protein(s) since there is evidence that -Syn itself may
function as chaperone that interacts with other proteins
(Souza et al., 2000b).
Since it has been shown that nitration of -Syn is a
common feature of pathological forms of this protein in LBs
of diverse synucleinopathies (Giasson et al., 2000a), it is
significant that similar changes were transiently seen fol-
lowing CCI here in aged WT mice because it is known that
TBI causes oxidative and nitrative stress (Clark et al., 2001;
Liu et al., 2002), including in WT rodents (Semchuk et al.,
1992) as well as in transgenic mouse models of AD-like
amyloidosis (Uryu et al., 2002). Further, the induction of
iNOS closely coincided with the temporal appearance of
nitrated -Syn in the brains of CCI-treated WT mice here,
and this suggests that TBI-induced iNOS may play a role in
transiently modifying the properties of -Syn following
TBI. Although it is unclear how nitrative stress contributes
to the development of -Syn pathology in human neurode-
generative diseases or TBI, previous studies suggest that
oxidative/nitrative stress may play a role in the aggregation
of -Syn (Paxinou et al., 2001; Norris et al., 2003) or in
stabilizing aggregated forms of -Syn (Souza et al., 2000a).
Thus, the data presented here suggest a possible link be-
tween TBI, oxidative/nitrative stress, and the generation of
-Syn pathology. Finally, the prominence of the enhanced
-Syn and -Syn IR in axons and the neuropil at 1–9 weeks
following TBI probably reflects a transient perturbation of
axonal transport that leads to the accumulation of multiple
organelles and proteins followed by the partial or complete
reversal of impaired transport and diminution of the abnor-
mal axonal -Syn and -Syn IR. Indeed, although the role
that altered axonal transport plays in TBI and neurodegen-
eration is unclear, there is growing evidence to implicate
perturbations of axonal transport in these disease processes.
However, in selected at-risk individuals, these changes may
not be completely reversed thereby predisposing these vic-
tims of head trauma to develop AD or PD many years after
the initial episode of TBI. While the precise nature of the
events that unfold over many years to link one or more
episodes of TBI to a greater risk for developing neurological
impairments is unclear, further investigations of experimen-
tal animal models of TBI such as those described here and
transgenic -Syn mice offer a tractable strategy for eluci-
dating how TBI-induced pathological modifications of
-Syn contribute to chronic neurodegeneration and behav-
ioral impairments.
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